Crossmark

Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients

Crossref DOI link: https://doi.org/10.1186/s12885-018-4220-1

Published Online: 2018-03-21

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bo, Xiaobo

Wang, Jie

Suo, Tao

Ni, Xiaoling

Liu, Han

Shen, Sheng

Li, Min

Wang, Yueqi

Liu, Houbao

Xu, Jiejie https://orcid.org/0000-0001-7431-9063
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81471621)

National Natural Science Foundation of China (81472227)

National Natural Science Foundation of China (81502004)

National Natural Science Foundation of China (81671628)

National Natural Science Foundation of China (31770851)

National Natural Science Foundation of China (81600630)

Shanghai municipal natural science foundation (16411952000)
License Information

Text and Data Mining valid from 2018-03-21
More Information

Article History

Received: 25 November 2017

Accepted: 13 March 2018

First Online: 21 March 2018

Ethics approval and consent to participate

: The study was approved by Fudan university, Zhongshan hospital research medical ethics committee (B2014–029). All specimens were obtained from patients with written informed consent.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.